Lemal R, et al. - In 55 patients with a symptomatic mast cell disorder, researchers evaluated omalizumab for its safety and efficacy. One patient (1.8%) had a complete response, a major response and a partial response was achieved for 30 patients (54.5%) and 12 patients (21.8%), respectively, causing an overall best response rate of 78.2% (43 of 55 patients). Findings revealed a dramatic efficacy of omalizumab on all superficial and general vasomotor symptoms and on most gastrointestinal or urinary symptoms. In addition, it was partially effective on most neuropsychiatric symptoms. An acceptable safety profile was displayed by omalizumab, except for one severe adverse event, which was edema of the larynx and dyspnea following the first injection. Overall, omalizumab seemed to have utility to control mast cell–mediator symptoms.